Most biological aging research focuses on what is happening inside your cells: methylation patterns on your DNA, glycan chains on your immunoglobulins, or the composition of proteins in your blood. These molecular approaches are the foundation of the field. They are also expensive, require clinical sample collection, and depend on laboratory processing that is invisible to the person being measured.
A parallel line of research asks a different question: can you extract useful aging information from signals that are easier to collect? A photograph. A step count. The way someone walks. Researchers call these “digital biomarkers” — quantitative measures derived from digital devices or AI analysis of observable data.
The idea is appealing. The evidence is early. And the gap between the two deserves careful attention.
What makes something a biomarker of ageing?
Before evaluating any specific digital approach, it helps to clarify what a biological aging biomarker is supposed to do. The field broadly agrees on a few requirements: a useful aging biomarker should change predictably with age, predict health outcomes beyond what chronological age already predicts, and ideally be responsive to interventions that affect aging biology.
The word “predict” matters here. A measure that correlates with age is not the same as one that tells you something new about your health trajectory. Blood pressure correlates with age, but it does not, by itself, count as a biological aging clock. The higher bar is: does this measure add information that your birth year does not already contain?
Digital biomarker research is mostly still working toward that higher bar. A lot of the published work establishes correlation with age, which is a starting point rather than a destination.
AI-based facial aging: what a photograph might reveal
One of the more provocative lines of digital biomarker research uses computer vision to estimate age from facial photographs. The underlying idea has intuitive appeal: your face reflects cumulative environmental exposures, sun damage, subcutaneous fat loss, and structural changes that are partly driven by the same biological processes as molecular aging.
A 2025 preprint by Kiraly, Fejes, and Kerepesi trained an AI model on more than 440,000 celebrity photographs and found that the resulting facial age estimate correlated with all-cause mortality in middle-aged and older individuals — a pattern consistent with the idea that facial appearance captures something real about aging biology. (Kiraly et al., biorxiv 2025 — preprint, not yet peer-reviewed)
The same study found that professional athletes in the dataset showed lower AI-estimated facial ages than most other occupational groups, which aligns directionally with the evidence on exercise and epigenetic aging.
The athlete finding illustrates a broader challenge with observational facial aging data. Professional athletes differ from the general population in exercise, diet, sleep, body composition, socioeconomic status, and genetics. Their lower facial age scores are consistent with a role for exercise, but they cannot be attributed to exercise alone. Survivorship bias also plays a role: only athletes who remain healthy and prominent enough to be frequently photographed appear in this kind of dataset.
For facial AI aging research to become clinically meaningful, it would need to demonstrate that its estimates predict health outcomes beyond what established biomarkers already capture, in cohorts representative of the general population, with controlled photographic conditions. That work has not yet been done.
Gait, grip strength, and functional aging signals
Physical performance measures occupy a more established position in aging research. Walking speed, grip strength, chair-stand time, and balance tests predict mortality, hospitalization, and functional decline in older adults with decent statistical robustness. These are not new ideas — they have been used in geriatric assessment for decades.
What is newer is the use of wearable sensors and accelerometers to capture these signals passively and continuously, rather than in a clinical assessment. Gait variability measured over thousands of steps may capture aspects of neuromotor aging that a brief walk-test cannot. Activity patterns across days and weeks may reflect energy metabolism and autonomic regulation in ways that a single measurement cannot.
The challenge is that most consumer wearables are not validated as aging biomarkers. They capture steps, heart rate, and sleep duration reasonably well. Whether the derived metrics — “fitness age,” “readiness score,” “stress level” — add meaningful aging information beyond raw activity data is largely unestablished. These are wellness features, not clinical aging tools.
Voice and cognitive digital biomarkers
A smaller but active area of research examines whether aging signatures can be extracted from speech patterns and cognitive tasks performed on digital devices. Voice characteristics change with age — vocal fold stiffness, breath support, and prosodic patterns all shift. Cognitive processing speed, measured in milliseconds on reaction time tasks, declines predictably with neurological aging.
These approaches are genuinely interesting as monitoring tools. But they face the same core problem as other digital biomarker research: correlation with age is well established, and incremental prediction of health outcomes beyond chronological age is far less established. A voice-age estimate that correlates with your calendar age is not the same as a tool that tells you whether your brain is aging faster or slower than expected.
How digital biomarkers relate to molecular clocks
It is worth being explicit about the relationship between digital and molecular aging measures, because they are often grouped under the same “biological age” umbrella when they are actually measuring quite different things.
Molecular clocks — epigenetic, glycomic, proteomic — measure changes at the cellular and subcellular level that are directly tied to the mechanisms of biological aging. They have been validated in large longitudinal cohorts and predict mortality and disease risk independently of chronological age. The validation work has been done, and it is substantial.
Digital biomarkers mostly measure downstream consequences or correlates of aging: how the biology manifests visually, functionally, or behaviorally. This is not inherently less valuable — functional aging matters enormously for quality of life — but it is a different layer of measurement with different validation requirements.
Treating a facial AI score or a wearable fitness age as equivalent to a validated epigenetic clock conflates two very different levels of evidence. The molecular layer currently has the stronger scientific foundation.
What this means for how you use these tools
Digital aging tools — including consumer apps that estimate your “biological age” from a selfie or your step count — can be engaging and motivating. There is nothing wrong with using them. But understanding what they do and do not measure prevents you from drawing conclusions the evidence does not yet support.
If you want a rigorous, scientifically validated measure of your biological aging rate, the current evidence points toward second-generation epigenetic clocks (GrimAge, DunedinPACE) or glycomic clocks (GlycanAge) measured from a blood sample. See how validated tests compare.
Digital biomarkers are likely to become more rigorous as the research matures. Multi-modal approaches — combining facial data, gait analysis, voice, and cognitive task performance — may eventually provide a non-invasive picture of biological aging that is more accessible and more longitudinally dense than periodic blood-based testing. The research is real and worth following. It is just not there yet.